OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events
Study for Preventing Heart Events in People with High Lipoprotein(a)
Brief description of study
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Cardiovascular Disease
-
Age: 50 years - 105 years
-
Gender: All
Inclusion Criteria:
- Age ≥50 years
- Lp(a)≥ 200 nmol/L during screening
- Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Exclusion Criteria:
- Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
- Prior or planned arterial revascularization
- History of major bleeding disorder
This study investigates cardiovascular events in individuals with elevated lipoprotein(a).
It evaluates the effect of an investigational medication on the risk of heart disease-related death and other major heart events.
- Who can participate: Adults aged 50 and older with high lipoprotein(a) levels can participate.
- Study details: Participants will receive either the investigational medication or a placebo.
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or